StockGlow

Celcuity Inc. (CELC)

Develops cancer drugs that block cell growth pathways in solid tumors

$82.46+0.00%Healthcare
Compare CELC with
StockGlow Score
58
Neutral
BearishBullish
1 year ago+106.6%

The outlook

CELC is trading flat today at $82.46, sitting well below both its 50- and 200-day moving averages after a recent pullback. Analysts are notably bullish with a Strong Buy consensus, and their average price target implies roughly 98% upside from current levels. The stock sits in the lower half of its 52-week range, reflecting recent weakness despite the positive analyst outlook.

What’s behind the score

Analyst consensusStrong Buy — 1.2 avg of 11 analysts
Price trendBelow its 50- & 200-day averages
52-week range41% of the way from its 52-week low to high
Price targetAvg target +98% vs current price

Analyst price target

~12-month · 11 analysts
$163.54average target+98.3% vs now
Now $82.46
Low $148.00High $178.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$4.02B
52-wk high
$151.02
52-wk low
$34.30
50-day avg
$104.46
200-day avg
$102.99
Trailing P/E
—

Similar stocks

ABVXABIVAX Société Anonyme$124.23-2.95%PRAXPraxis Precision Medicines, Inc.$295.81-6.33%CRNXCrinetics Pharmaceuticals, Inc.$83.86+0.01%REPLReplimune Group, Inc.$5.35-38.01%SRRKScholar Rock Holding Corporation$49.37+0.90%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy